 |  |    |
 |  |
About Our Team Erik Tjaden, Ph.D., CEO and President Philip Korb, Group Leader, Radiochemistry Tim Smith, Ph.D., Research Scientist Erik Tjaden, Ph.D., CEO and PresidentDr. Tjaden is a co-founder of Tjaden Biosciences. Dr. Tjaden received his B.S. in Chemistry from the University of Iowa in 1987 and his Ph.D. in Chemistry from Indiana University in 1993. Following a one-year post-doctoral assignment at the University of Iowa, Dr. Tjaden joined the Union Carbide Catalyst Skill Center in S. Charleston, West Virginia. At Union Carbide, Dr. Tjaden was involved in the research and development of new catalysts and catalytic processes. After 6 years at Union Carbide, Dr. Tjaden joined Analytical-Biochemistry Laboratories in Columbia, Missouri. At ABC Labs, Dr. Tjaden started and directed the synthesis group overseeing projects including carbon-14 and tritium custom synthesis, GMP production, analytical method development and validation, radiopharmaceutical drug product investigation and production, and impurity identification and isolation.Philip Korb, Group Leader, RadiochemistryMr. Korb has over 40 years of radiochemical experience and is recognized as an expert in the production of carbon-14 intermediates from barium carbonate. Mr. Korb received his B.S. in Chemistry from Stetson University in 1961. Mr. Korb's vast industrial experience includes tenures at many radiochemical facilities including Mallinckrodt/Nuclear from 1964-1973, New England Nuclear (now Perkin Elmer) from 1973-1979, KOR Isotopes in 1979, Pathfinder Laboratories (now Sigma) from 1980-1981, and American Radiolabeled Chemicals from 1983-2006. Many of Mr. Korb's contributions to the radiochemical field including laboratory design, vacuum line design and usage, and radiochemical production procedures are now viewed as industry standards.Tim Smith, Ph.D., Research ScientistDr. Smith received his B.S. in Chemistry from the University of Iowa in 1986 and his Ph.D. in Chemistry from the University of California at Berkeley in 1991. After a post-doctoral assignment at the University of Bern in Switzerland investigating the synthesis of xenicanes, Dr. Smith spent nine years in academics holding a variety of teaching positions and conducting research in the areas of Diels-Alder and epoxide rearrangement reactions, and computational studies on manganese complexes. In 2002, Dr. Smith joined Semafore Pharmaceuticals and was responsible for identifying and developing synthetic routes for the Semafore new drug candidates. In December 2006, Dr. Smith joined Tjaden Biosciences as a Research Scientist. |
|
 | |